文献速递泌尿生殖腹部CTMR

2019版Bosniak分类囊性肾肿块:按类别和亚类的恶性比例——系统综述与荟萃分析

Bosniak Classification of Cystic Renal Masses Version 2019: Proportion of Malignancy by Class and Subclass-Systematic Review and Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2025-01-08

该系统综述与荟萃分析纳入12项研究共966例患者975个囊性肾肿块,按2019版Bosniak分类评估恶性比例。I类无恶性;II类9%,IIF类26%,III类80%,IV类88%。IIF类中以组织病理为参考标准者恶性比例41%,以影像随访为参考标准者仅2%,提示验证偏倚。

要点

  • 2019版Bosniak I类囊性肾肿块无恶性,II类恶性比例9%。
  • IIF类总体恶性26%,但以病理为参考标准者达41%,影像随访者仅2%。
  • III类各亚类恶性比例均高(78%–84%),IV类各亚类亦高(86%–88%)。

核心结论

  • 2019版Bosniak IIF类囊性肾肿块以组织病理为参考标准时恶性比例高于以影像随访为参考标准,提示存在验证偏倚。
  • 2019版Bosniak III类和IV类的所有亚类恶性比例均高。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Embase数据库(2023年7月24日),纳入2019年及以后发表、采用2019版Bosniak分类评估囊性肾肿块且具有参考标准的研究。
  • 共纳入12项研究,966例患者,975个囊性肿块;参考标准为组织病理(良性或恶性)或≥5年影像随访提示良性。
  • 联系研究作者以获取按亚类分层的数据,采用荟萃分析计算按2019版分类和亚类分层的恶性比例合并值。

诊断标准与关键数值

  • 按2019版Bosniak分类的恶性比例合并值:I类无恶性;II类9%(95%CI:5–17%);IIF类26%(95%CI:13–46%);III类80%(95%CI:71–87%);IV类88%(95%CI:83–91%)。
  • IIF类亚类恶性比例:许多光滑薄分隔者10%(95%CI:2–33%);壁或分隔轻微增厚者47%(95%CI:18–77%);T1不均匀高信号者26%(95%CI:8–57%)。
  • III类亚类恶性比例:厚而光滑的壁或分隔者78%(95%CI:60–90%);≤3 mm钝角突起者84%(95%CI:77–90%)。
  • IV类亚类恶性比例:任何尺寸锐角突起者88%(95%CI:80–93%);≥4 mm钝角突起者86%(95%CI:77–91%)。
  • IIF类以组织病理为参考标准者恶性比例41%,以影像随访为参考标准者2%。

临床应用与阅片要点

  • 2019版Bosniak I类囊性肾肿块无恶性,II类恶性比例低(9%)。
  • IIF类总体恶性比例26%,但不同亚类差异大:许多光滑薄分隔者10%,壁或分隔轻微增厚者47%,T1不均匀高信号者26%。
  • III类各亚类恶性比例均高:厚而光滑的壁或分隔者78%,≤3 mm钝角突起者84%。
  • IV类各亚类恶性比例亦高:任何尺寸锐角突起者88%,≥4 mm钝角突起者86%。
  • IIF类以病理为参考标准者恶性比例(41%)明显高于以影像随访为参考标准者(2%),判读时需注意参考标准带来的验证偏倚。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Bosniak classification version 2019 (v2019) was a major revision to version 2005 (v2005) that defined cystic renal mass subclasses on the basis of wall or septa features. OBJECTIVE. The purpose of the study was to determine the proportion of malignancy within cystic renal masses stratified by Bosniak classification v2019 class and feature-based subclass. EVIDENCE ACQUISITION. MEDLINE and Embase databases were searched on July 24, 2023, for studies published in 2019 or later that reported cystic renal masses that underwent renal-mass CT or MRI, were assessed using Bosniak classification v2019, and had a reference standard (histopathology indicating benignancy or malignancy or ≥ 5 years of imaging follow-up indicating benignancy). Study authors were contacted to provide subclass-stratified data. Pooled proportions of malignancy stratified by v2019 class and subclass were determined using meta-analysis. EVIDENCE SYNTHESIS. The analysis included 12 studies reporting 966 patients with 975 cystic masses. No class I mass was malignant. Pooled proportions of malignancy by class were as follows: II, 9% (95% CI: 5-17%); IIF, 26% (95% CI: 13-46%); III, 80% (95% CI: 71-87%); and IV, 88% (95% CI: 83-91%). Pooled proportions of malignancy by subclass were as follows: IIF with many smooth, thin septa, 10% (95% CI: 2-33%); IIF with minimal wall or septal thickening, 47% (95% CI: 18-77%); IIF with heterogeneous T1 hyperintensity, 26% (95% CI: 8-57%); III with a thick, smooth wall or septa, 78% (95% CI: 60-90%); III with obtuse protrusion(s) 3 mm or less, 84% (95% CI: 77-90%); IV with acute protrusion(s) of any size, 88% (95% CI: 80-93%); and IV with obtuse protrusion(s) 4 mm or greater, 86% (95% CI: 77-91%). The proportion of malignancy was 41% for IIF masses with histopathology reference versus 2% for IIF masses with imaging follow-up reference. In four studies performing intraindividual comparisons of v2005 versus v2019, the proportions of malignancy were as follows: class IIF, 24% versus 42% (p = .13); III, 74% versus 77% (p = .72); and IV, 79% versus 84% (p = .22). CONCLUSION. Bosniak IIF masses had higher malignancy rates when histopathology rather than imaging follow-up was the reference standard, indicating verification bias. All Bosniak III and IV subclasses had high malignancy rates. CLINICAL IMPACT. The results improve understanding of imaging-based cystic renal-mass classification and may inform development of future renal-mass classification systems. TRIAL REGISTRATION. PROSPERO (International Prospective Register of Systematic Reviews) CRD42023472140.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. McGrath TA, Davenport MS, Silverman SG, et al. Bosniak Classification of Cystic Renal Masses Version 2019: Proportion of Malignancy by Class and Subclass-Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2025. PMID: 39772585. doi:10.2214/AJR.24.32342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。